Keywords:
Inclisiran; PCSK9 Inhibition; Patient Adherence; Biannual Injections; Hyperlipidemia; Cardiovascular Risk; Real-World Study; Lipid Management; Medication Compliance; LDL-C Reduction
Abstract
Inclisiran, a small interfering RNA targeting PCSK9, has emerged as a transformative biannual lipid-lowering therapy with the potential to address adherence challenges common in daily and weekly statin-based regimens. This study investigates real-world patient adherence patterns associated with biannual Inclisiran administration across multiple tertiary care centers. By retrospectively analyzing medical records, pharmacy refill data, and follow-up documentation from diverse populations, the study seeks to determine whether the simplified dosing regimen correlates with higher patient adherence, sustained LDL-C reduction, and improved cardiovascular outcomes. Results from this study offer critical insights into the patient behavior surrounding novel lipid-lowering therapies and provide evidence to inform future guideline recommendations and payer coverage decisions. The findings underscore that longer dosing intervals may play a pivotal role in improving long-term compliance among at-risk cardiovascular populations.
References
- Benner, J. S., Glynn, R. J., Mogun, H., Neumann, P. J., Weinstein, M. C., Sacks, F. M., & Avorn, J. (2002). Long-term persistence in use of statin therapy in elderly patients. JAMA, 288(4), 455–461. https://doi.org/10.1001/jama.288.4.455
- Ho, P. M., Magid, D. J., Shetterly, S. M., Olson, K. L., Maddox, T. M., Peterson, P. N., Masoudi, F. A., & Rumsfeld, J. S. (2006). Medication nonadherence is associated with increased hospitalization and mortality: A population-based study. Circulation, 113(23), 2841–2847. https://doi.org/10.1161/CIRCULATIONAHA.105.591255
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., … & Koren, M. J. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine, 372(16), 1500–1509. https://doi.org/10.1056/NEJMoa1500858
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., … & Stein, E. A. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine, 372(16), 1489–1499. https://doi.org/10.1056/NEJMoa1501031
- Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., … & Simon, A. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. The New England Journal of Medicine, 376(1), 41–51. https://doi.org/10.1056/NEJMoa1609222
- Ray, K. K., Robinson, J. G., Farnier, M., Krempf, M., MacDougall, D. E., & Sullivan, D. (2017). Safety and efficacy of alirocumab over 104 weeks in adults with hypercholesterolaemia. International Journal of Cardiology, 238, 1–7. https://doi.org/10.1016/j.ijcard.2017.02.070
- Fischer, M. A., Choudhry, N. K., Brill, G., Avorn, J., Schneeweiss, S., Hutchins, D., & Shrank, W. H. (2010). Trouble getting started: Predictors of primary medication nonadherence. The American Journal of Medicine, 123(9), 707–714. https://doi.org/10.1016/j.amjmed.2010.04.012
- Peterson, G. M., & Naunton, M. (2005). Adherence to long-term therapies: Evidence for action. Medical Journal of Australia, 183(3), 205–206. https://doi.org/10.5694/j.1326-5377.2005.tb06817.x
- Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., … & Haynes, R. B. (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, (11), CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
- Jackevicius, C. A., Li, P., & Tu, J. V. (2002). Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation, 109(13), 1611–1618. https://doi.org/10.1161/01.CIR.0000122007.84860.CC
How to cite
Sanya Thakur (2017). Patient Adherence Patterns with Biannual Inclisiran Injections: A Multi-Center Real-World Study. International Journal for Research in Management & Pharmacy, 6(11).
Licence
This article is open access, published under the CC BY 4.0 licence. Copyright remains with the authors.
If the issue persists, you can use the old publisher details where you get it published.